Morgan Stanley Maintains Overweight on Enfusion, Lowers Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst James Faucette has maintained an Overweight rating on Enfusion (NYSE:ENFN), but lowered the price target from $12 to $11.
August 09, 2023 | 12:50 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley has maintained an Overweight rating on Enfusion, but lowered the price target from $12 to $11.
The news is directly related to Enfusion. While the Overweight rating is positive, the lowering of the price target may have a neutral to slightly negative impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100